novo nordisk glp 1 drugs Details of failed studies cast pall on Nordisk's GLP-1 as Alzheimer's treatment Novo Nordisk's oral GLP-1 drug

That hormone can tell your brain you're full, slow digestion and curb cravings, especially for carbohydrates

doi: 10.1203/00006450-200106000-00003 22

However, the repeated failure of A-targeted therapies in clinical trials highlights the limitations of focusing on a single pathological mechanism

Results May Vary: Individual results will vary based on factors including age, baseline weight, metabolic health, genetic factors, consistency of medication use, dietary choices, physical activity levels, sleep quality, stress levels, current medications, and other individual variables

Around 90% of the over 37 million Americans with diabetes have Type 2 diabetes, a condition associated with obesity, according to the CDC